CORP — CORPORATE / INDUSTRY

Danaher–IGI Beacon for CRISPR Cures (partnering route)

Danaher & Innovative Genomics Institute

Award

Funded collaborative platform (no open call)

Deadline

No open call — diseases selected internally

Award type

Partnership route

Focus

Preclinical & therapeutics

A funded UC Berkeley and UCSF centre building a scalable platform for CRISPR therapies for rare monogenic diseases, with initial targets in inborn errors of immunity. There is no external application mechanism — diseases are chosen internally.

Why it's in this index

The route in is contact with IGI or its clinical collaborators, presenting a monogenic case such as TAFAZZIN. Treat this as advocacy rather than an application.

Who can apply

Invited collaborations only.

How to apply

Outreach to the Innovative Genomics Institute (innovativegenomics.org) or clinical collaborators.

Links & downloads

IGI announcement ↗